{"filing":{"accession_number":"0001703057-26-000033","cik":"0001703057","ticker":"ABCL","company_name":"AbCellera Biologics Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"abcl-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000033/abcl-20260611.htm"},"events":[{"id":5237,"run_id":4590,"accession_number":"0001703057-26-000033","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from AbCellera's Annual Meeting of Shareholders held on June 11, 2026. The filing reports voting outcomes for three proposals: (i) election of two Class III directors (John S. Montalbano and Stephen R. Quake), (ii) ratification of Ernst \u0026 Young LLP as independent auditor, and (iii) advisory approval of named executive officer compensation. All three proposals were approved by shareholders, with detailed vote tallies provided for each. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms board composition and auditor ratification.","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6519,"accession_number":"0001703057-26-000033","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from AbCellera's Annual Meeting of Shareholders held on June 11, 2026. The filing reports voting outcomes for three proposals: (i) election of two Class III directors (John S. Montalbano and Stephen R. Quake), (ii) ratification of Ernst \u0026 Young LLP as independent auditor, and (iii) advisory approval of named executive officer compensation. All three proposals were approved by shareholders, with detailed vote tallies provided for each. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms board composition and auditor ratification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-12T16:13:05.970208+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6519,"accession_number":"0001703057-26-000033","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from AbCellera's Annual Meeting of Shareholders held on June 11, 2026. The filing reports voting outcomes for three proposals: (i) election of two Class III directors (John S. Montalbano and Stephen R. Quake), (ii) ratification of Ernst \u0026 Young LLP as independent auditor, and (iii) advisory approval of named executive officer compensation. All three proposals were approved by shareholders, with detailed vote tallies provided for each. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms board composition and auditor ratification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-12T16:13:05.970208+00:00","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-06-12"}]}